MX2023009186A - Proteinas de fusion de il-15 y metodos para preparacion y uso de las mismas. - Google Patents
Proteinas de fusion de il-15 y metodos para preparacion y uso de las mismas.Info
- Publication number
- MX2023009186A MX2023009186A MX2023009186A MX2023009186A MX2023009186A MX 2023009186 A MX2023009186 A MX 2023009186A MX 2023009186 A MX2023009186 A MX 2023009186A MX 2023009186 A MX2023009186 A MX 2023009186A MX 2023009186 A MX2023009186 A MX 2023009186A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- methods
- making
- same
- recombinant fusion
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La divulgación proporciona proteínas de fusión recombinantes que comprenden un dominio de unión a antígeno específico para CTLA-4, un dominio sushi de IL-15Ra e IL-15. La divulgación proporciona además métodos de uso de estas proteínas de fusión recombinantes en el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163146242P | 2021-02-05 | 2021-02-05 | |
PCT/US2022/015271 WO2022170063A1 (en) | 2021-02-05 | 2022-02-04 | Il-15 fusion proteins and methods of making and using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2023009186A true MX2023009186A (es) | 2023-08-21 |
Family
ID=80952466
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023009186A MX2023009186A (es) | 2021-02-05 | 2022-02-04 | Proteinas de fusion de il-15 y metodos para preparacion y uso de las mismas. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4288154A1 (es) |
JP (1) | JP2024506292A (es) |
KR (1) | KR20230166078A (es) |
CN (1) | CN117242099A (es) |
AU (1) | AU2022217812A1 (es) |
CA (1) | CA3206844A1 (es) |
IL (1) | IL304916A (es) |
MX (1) | MX2023009186A (es) |
WO (1) | WO2022170063A1 (es) |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
KR20190091264A (ko) * | 2016-10-21 | 2019-08-05 | 알토 바이오사이언스 코포레이션 | 다량체 il-15 기반 분자 |
JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス, インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
SG11202010163QA (en) * | 2018-04-18 | 2020-11-27 | Xencor Inc | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
CA3097625A1 (en) * | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof |
AU2019256520A1 (en) * | 2018-04-18 | 2020-11-26 | Xencor, Inc. | LAG-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and LAG-3 antigen binding domains |
US11634467B2 (en) * | 2018-06-22 | 2023-04-25 | Cugene Inc. | Cytokine-based bioactivatable drugs and methods of uses thereof |
JP2022536898A (ja) * | 2019-06-12 | 2022-08-22 | アスクジーン・ファーマ・インコーポレイテッド | 新規il-15プロドラッグおよびその使用方法 |
CN114901679A (zh) * | 2020-01-11 | 2022-08-12 | 奥美药业有限公司 | 全新被掩蔽的细胞因子及其应用 |
-
2022
- 2022-02-04 CA CA3206844A patent/CA3206844A1/en active Pending
- 2022-02-04 WO PCT/US2022/015271 patent/WO2022170063A1/en active Application Filing
- 2022-02-04 EP EP22713103.4A patent/EP4288154A1/en active Pending
- 2022-02-04 IL IL304916A patent/IL304916A/en unknown
- 2022-02-04 KR KR1020237030091A patent/KR20230166078A/ko unknown
- 2022-02-04 AU AU2022217812A patent/AU2022217812A1/en active Pending
- 2022-02-04 JP JP2023547194A patent/JP2024506292A/ja active Pending
- 2022-02-04 CN CN202280026009.2A patent/CN117242099A/zh active Pending
- 2022-02-04 MX MX2023009186A patent/MX2023009186A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2022217812A1 (en) | 2023-08-03 |
CN117242099A (zh) | 2023-12-15 |
CA3206844A1 (en) | 2022-08-11 |
WO2022170063A1 (en) | 2022-08-11 |
IL304916A (en) | 2023-10-01 |
KR20230166078A (ko) | 2023-12-06 |
EP4288154A1 (en) | 2023-12-13 |
JP2024506292A (ja) | 2024-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202100390B (en) | Fusion constructs and methods of using thereof | |
MX2022009947A (es) | Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos. | |
MX2020010910A (es) | Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos. | |
PH12020550860A1 (en) | Anti-trem2 antibodies and related methods | |
AU2018449846A8 (en) | An anti-B7-H3 antibody | |
WO2019224716A3 (en) | Antibodies specific for gucy2c and uses thereof | |
MX2021015888A (es) | Fusión de un anticuerpo que se une a cea y 4-1bbl. | |
MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
PH12017501347A1 (en) | Agonistic icos binding proteins | |
WO2018187356A3 (en) | Protein antigens and uses thereof | |
PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
MD3353212T2 (ro) | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora | |
JOP20160154B1 (ar) | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها | |
AU2019415848A8 (en) | Claudin18.2 binding moieties and uses thereof | |
MX2020009116A (es) | Proteinas triespecificas de union a antigenos. | |
AU2018338322A1 (en) | A33 antibody compositions and methods of using the same in radioimmunotherapy | |
MX2020013017A (es) | Materiales y metodos para tratar cancer. | |
WO2019056023A3 (en) | Claudin6 antibodies and methods of treating cancer | |
AU2018338423A1 (en) | Novel anti-HLA-A2 antibodies and uses thereof | |
PH12020552270A1 (en) | Anti-steap1 antigen-binding protein | |
WO2022082073A3 (en) | Compositions and methods for muc18 targeting | |
MX2021004993A (es) | Materiales y metodos para tratar cancer. | |
WO2022024024A3 (en) | Proteins comprising hla-g antigen binding domains and their uses | |
MX2021011040A (es) | Anticuerpos dirigidos contra c5ar. | |
MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). |